Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Convertible Debt (2016 - 2021)

Fortress Biotech has reported Convertible Debt over the past 3 years, most recently at $18.1 million for Q3 2021.

  • Quarterly results put Convertible Debt at $18.1 million for Q3 2021, changed N/A from a year ago — trailing twelve months through Sep 2021 was $18.1 million (changed N/A YoY), and the annual figure for FY2017 was $10.1 million, up 175.14%.
  • Convertible Debt for Q3 2021 was $18.1 million at Fortress Biotech, up from $12.5 million in the prior quarter.
  • Over the last five years, Convertible Debt for FBIO hit a ceiling of $18.1 million in Q3 2021 and a floor of $1.5 million in Q2 2017.